Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical Technology Enterprise Consortium, 22119-22120 [2016-08574]

Download as PDF Federal Register / Vol. 81, No. 72 / Thursday, April 14, 2016 / Notices treated accordingly. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.5 This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of §§ 201.10 and 210.8(c) of the Commission’s Rules of Practice and Procedure (19 CFR 201.10 and 210.8(c)). BILLING CODE P Notice Pursuant to the National Cooperative Research and Production Act of 1993—Pistoia Alliance, Inc. BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cable Television Laboratories, Inc. mstockstill on DSK4VPTVN1PROD with NOTICES [FR Doc. 2016–08582 Filed 4–13–16; 8:45 am] Antitrust Division [FR Doc. 2016–08624 Filed 4–13–16; 8:45 am] Notice is hereby given that, on March 17, 2016, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Cable Television Laboratories, Inc. (‘‘CableLabs’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Zegona Communications, plc, London, UNITED KINGDOM; Euskaltel, S.A., Derio, SPAIN; and Cable Onda, S.A., Panama, PANAMA, have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and CableLabs intends to file additional written notifications disclosing all changes in membership. On August 8, 1988, CableLabs filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on September 7, 1988 (53 FR 34593). The last notification was filed with the Department on December 11, 2014. A notice was published in the Federal 5 Electronic Document Information System (EDIS): http://edis.usitc.gov. 17:56 Apr 13, 2016 Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. DEPARTMENT OF JUSTICE By order of the Commission. Issued: April 11, 2016. Lisa R. Barton, Secretary to the Commission. VerDate Sep<11>2014 Register pursuant to Section 6(b) of the Act on February 6, 2015 (80 FR 6769). Jkt 238001 Notice is hereby given that, on March 8, 2016, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Pistoia Alliance, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Leah McEwan (individual member), Ithaca, NY; Yannick Djoumbou Feunang (individual member), Edmonton, CANADA; Louis Fisher (individual member), Plantation, FL; SciBite, Cambridge, UNITED KINGDOM; and Monocl Software, Gothenberg, SWEDEN, have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Pistoia Alliance, Inc. intends to file additional written notifications disclosing all changes in membership. On May 28, 2009, Pistoia Alliance, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on July 15, 2009 (74 FR 34364). The last notification was filed with the Department on December 21, 2015. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on February 26, 2016 (81 FR 9883). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2016–08579 Filed 4–13–16; 8:45 am] BILLING CODE P PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 22119 DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on Advanced Combustion Catalyst and Aftertreatment Technologies Notice is hereby given that, on March 15, 2016, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Southwest Research Institute—Cooperative Research Group on Advanced Combustion Catalyst and Aftertreatment Technologies (‘‘AC2AT’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Scania, Sodertalje, SWEDEN, and Volvo Technology AB, Goteborg, SWEDEN, have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and AC2AT intends to file additional written notifications disclosing all changes in membership. On March 20, 2015, AC2AT filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on April 30, 2015 (80 FR 24277). The last notification was filed with the Department on January 27, 2016. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on March 9, 2016 (81 FR 12526). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2016–08571 Filed 4–13–16; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium Notice is hereby given that, on March 15, 2016, pursuant to Section 6(a) of the National Cooperative Research and E:\FR\FM\14APN1.SGM 14APN1 mstockstill on DSK4VPTVN1PROD with NOTICES 22120 Federal Register / Vol. 81, No. 72 / Thursday, April 14, 2016 / Notices Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), the Medical Technology Enterprise Consortium (‘‘MTEC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership and nature and objectives. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Agile Immersive, Arlington, VA; Armed Forces Institute for Regenerative Medicine (AFIRM), Winston-Salem, NC; Articulate Biomedical, LLC, Ithaca, NY; BioMed SA, San Antonio, TX; Cedars-Sinai Medical Center, Los Angeles, CA; CUBRC, Inc., Buffalo, NY; Eagle Applied Sciences, LLC, San Antonio, TX; East Carolina University, Greenville, NC; FirstString Research, Inc., Mt. Pleasant, SC; Gateway Biotechnology, Inc., Kent, OH; General Electric Company, Global Research, Niskayuna, NY; Georgia Tech Research Corporation, Atlanta, GA; IDIQ, Inc., Fallbrook, CA; InnoVital Systems, Inc., Beltsville, MD; Johns Hopkins University, Baltimore, MD; and Kestrel Corporation, Albuquerque, NM, Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM; McAllister & Quinn, LLC, Washington, DC; Medical University of South Carolina, Charleston, SC; MedPro Technologies, Inc., San Antonio, TX; Michigan Technological University, Houghton, MI; MicroCures, Inc., Santa Cruz, CA; MiMedx Group, Inc., Marietta, GA; New York Institute of Technology, Old Westbury, NY; North American Rescue, LLC, Greer, SC; Otologic Pharmaceutics, Inc., Oklahoma City, OK; Pertexa Healthcare Technologies, Inc., Ridgecrest, CA; Qool Therapeutics, Inc., Menlo Park, CA; RegenMed Development Organization, Winston-Salem, NC; Resiliency Technologies, Inc., Spartanburg, SC; Second Sight Medical Products, Inc., Sylmar, CA; Southwest Research Institute, San Antonio, TX; Techline Technologies, Inc., Willow Grove, PA; The Conafay Group, Washington, DC; The General Hospital Corporation dba Massachusetts General Hospital, Boston, MA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; The Ohio State University, Columbus, OH; The Research Foundation for the State University of New York (SUNY), Syracuse, NY; The University of Texas at Arlington Research Institute (UTARI), Arlington, TX; Trideum Biosciences, VerDate Sep<11>2014 17:56 Apr 13, 2016 Jkt 238001 Frederick, MD; Triton Systems, Inc., Chelmsford, MA; University of Illinois at Chicago, Chicago, IL; University of Miami, Coral Gables, FL; University of Michigan, Ann Arbor, MI; University of Nebraska Medical Center, Omaha, NE; University of Pittsburgh, Pittsburgh, PA; University of South Carolina, Columbia, SC; University of Virginia, Charlottesville, VA; Vanderbilt University School of Engineering, Nashville, TN; Wake Forest University Health Sciences, Winston-Salem, NC; and Weinberg Medical Physics, LLC, North Bethesda, MD, have been added as parties to this venture. Also, Biohealth Innovation, Inc., Rockville, MD; Center for Integration of Medicine and Innovative Technology (CIMIT), Boston, MA; Florida Atlantic University, Boca Raton, FL; Indiana University, Bloomington, IN; Institute for Systems Biology, Seattle, WA; Jade Therapeutics, Inc., Salt Lake City, UT; Johns Hopkins Technology Transfer, Baltimore, MD; KAI Research, Inc. (KAI), Rockville, MD; Human Effects Modeling, Advanced Technology, Inc., L–3 Communications, San Diego, CA; Maryland Technology Development Corp. (TEDCO), Columbia, MD; and Institute for Collaborative Biotechnologies, University of California, Santa Barbara, CA, have withdrawn as parties to this venture. The general areas of MTEC’s planned activity are to: (a) enter into an Other Transactions Agreement with the U.S. Army Medical Research and Materiel Command (the Government) to fund certain research, development, and commercialization efforts conducted in partnership with the Government, the Consortium, and Consortium Members that enhance the medical knowledge and life cycle management of the medical program, and enable the Government to better protect, treat, and optimize Warfighter health and performance across the full spectrum of operations; (b) participate in establishing sound technical and programmatic performance goals based on the needs and requirements of the Government’s Technology Objectives and other mission requirements; (c) create programs and secure funding; (d) provide a unified voice that effectively articulates the strategically important role military medical technologies play in current and future military operations; and (e) maximize use of Government and member capabilities and resources for developing critical processes, procedures, drugs, vaccines, and devices that can be transitioned and commercialized for both military and civilian use. PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MTEC intends to file additional written notifications disclosing all changes in membership. On May 9, 2014, MTEC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2016–08574 Filed 4–13–16; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—National Spectrum Consortium Notice is hereby given that, on March 15, 2016, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), National Spectrum Consortium (‘‘NSC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, SAZE Technologies, LLC, Silver Spring, MD; The University of Chicago, Chicago, IL; Rohde & Schwarz USA, Inc., Columbia, MD; Board of Regents, NSHE, obo University of Nevada Reno, Reno, NV; Continental Microwave & Tool, Co. Inc. d/b/a Cobham Advanced Electronic Solutions, Exeter, NH; and Eridan Communications, Inc., San Francisco, CA, have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NSC intends to file additional written notifications disclosing all changes in membership. On May 24, 2014, NSC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on November 4, 2014 (79 FR 65424). E:\FR\FM\14APN1.SGM 14APN1

Agencies

[Federal Register Volume 81, Number 72 (Thursday, April 14, 2016)]
[Notices]
[Pages 22119-22120]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-08574]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical Technology Enterprise Consortium

    Notice is hereby given that, on March 15, 2016, pursuant to Section 
6(a) of the National Cooperative Research and

[[Page 22120]]

Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''), the 
Medical Technology Enterprise Consortium (``MTEC'') has filed written 
notifications simultaneously with the Attorney General and the Federal 
Trade Commission disclosing changes in its membership and nature and 
objectives. The notifications were filed for the purpose of extending 
the Act's provisions limiting the recovery of antitrust plaintiffs to 
actual damages under specified circumstances. Specifically, Agile 
Immersive, Arlington, VA; Armed Forces Institute for Regenerative 
Medicine (AFIRM), Winston-Salem, NC; Articulate Biomedical, LLC, 
Ithaca, NY; BioMed SA, San Antonio, TX; Cedars-Sinai Medical Center, 
Los Angeles, CA; CUBRC, Inc., Buffalo, NY; Eagle Applied Sciences, LLC, 
San Antonio, TX; East Carolina University, Greenville, NC; FirstString 
Research, Inc., Mt. Pleasant, SC; Gateway Biotechnology, Inc., Kent, 
OH; General Electric Company, Global Research, Niskayuna, NY; Georgia 
Tech Research Corporation, Atlanta, GA; IDIQ, Inc., Fallbrook, CA; 
InnoVital Systems, Inc., Beltsville, MD; Johns Hopkins University, 
Baltimore, MD; and Kestrel Corporation, Albuquerque, NM, Lovelace 
Biomedical and Environmental Research Institute, Albuquerque, NM; 
McAllister & Quinn, LLC, Washington, DC; Medical University of South 
Carolina, Charleston, SC; MedPro Technologies, Inc., San Antonio, TX; 
Michigan Technological University, Houghton, MI; MicroCures, Inc., 
Santa Cruz, CA; MiMedx Group, Inc., Marietta, GA; New York Institute of 
Technology, Old Westbury, NY; North American Rescue, LLC, Greer, SC; 
Otologic Pharmaceutics, Inc., Oklahoma City, OK; Pertexa Healthcare 
Technologies, Inc., Ridgecrest, CA; Qool Therapeutics, Inc., Menlo 
Park, CA; RegenMed Development Organization, Winston-Salem, NC; 
Resiliency Technologies, Inc., Spartanburg, SC; Second Sight Medical 
Products, Inc., Sylmar, CA; Southwest Research Institute, San Antonio, 
TX; Techline Technologies, Inc., Willow Grove, PA; The Conafay Group, 
Washington, DC; The General Hospital Corporation dba Massachusetts 
General Hospital, Boston, MA; The Henry M. Jackson Foundation for the 
Advancement of Military Medicine, Bethesda, MD; The Ohio State 
University, Columbus, OH; The Research Foundation for the State 
University of New York (SUNY), Syracuse, NY; The University of Texas at 
Arlington Research Institute (UTARI), Arlington, TX; Trideum 
Biosciences, Frederick, MD; Triton Systems, Inc., Chelmsford, MA; 
University of Illinois at Chicago, Chicago, IL; University of Miami, 
Coral Gables, FL; University of Michigan, Ann Arbor, MI; University of 
Nebraska Medical Center, Omaha, NE; University of Pittsburgh, 
Pittsburgh, PA; University of South Carolina, Columbia, SC; University 
of Virginia, Charlottesville, VA; Vanderbilt University School of 
Engineering, Nashville, TN; Wake Forest University Health Sciences, 
Winston-Salem, NC; and Weinberg Medical Physics, LLC, North Bethesda, 
MD, have been added as parties to this venture.
    Also, Biohealth Innovation, Inc., Rockville, MD; Center for 
Integration of Medicine and Innovative Technology (CIMIT), Boston, MA; 
Florida Atlantic University, Boca Raton, FL; Indiana University, 
Bloomington, IN; Institute for Systems Biology, Seattle, WA; Jade 
Therapeutics, Inc., Salt Lake City, UT; Johns Hopkins Technology 
Transfer, Baltimore, MD; KAI Research, Inc. (KAI), Rockville, MD; Human 
Effects Modeling, Advanced Technology, Inc., L-3 Communications, San 
Diego, CA; Maryland Technology Development Corp. (TEDCO), Columbia, MD; 
and Institute for Collaborative Biotechnologies, University of 
California, Santa Barbara, CA, have withdrawn as parties to this 
venture.
    The general areas of MTEC's planned activity are to: (a) enter into 
an Other Transactions Agreement with the U.S. Army Medical Research and 
Materiel Command (the Government) to fund certain research, 
development, and commercialization efforts conducted in partnership 
with the Government, the Consortium, and Consortium Members that 
enhance the medical knowledge and life cycle management of the medical 
program, and enable the Government to better protect, treat, and 
optimize Warfighter health and performance across the full spectrum of 
operations; (b) participate in establishing sound technical and 
programmatic performance goals based on the needs and requirements of 
the Government's Technology Objectives and other mission requirements; 
(c) create programs and secure funding; (d) provide a unified voice 
that effectively articulates the strategically important role military 
medical technologies play in current and future military operations; 
and (e) maximize use of Government and member capabilities and 
resources for developing critical processes, procedures, drugs, 
vaccines, and devices that can be transitioned and commercialized for 
both military and civilian use.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MTEC intends to file additional 
written notifications disclosing all changes in membership.
    On May 9, 2014, MTEC filed its original notification pursuant to 
Section 6(a) of the Act. The Department of Justice published a notice 
in the Federal Register pursuant to Section 6(b) of the Act on June 9, 
2014 (79 FR 32999).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2016-08574 Filed 4-13-16; 8:45 am]
 BILLING CODE P